AUTH/3805/7/23 - Complainant v ViiV

Alleged advertisement of Apretude to the public

  • Case number
    AUTH/3805/7/23
  • Complaint received
    29 July 2023
  • Completed
    13 February 2025
  • Appeal hearing
    Appeal by the respondent
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to an advertisement being visible to a member of the public in the UK while they were using a dating app. The advertisement was for Apretude (cabotegravir), an injectable medication which at the time of the complaint was licensed for use in the USA for HIV-1 PrEP to reduce the risk of getting HIV-1 infection.

There was an appeal by Viiv Healthcare UK of one of the Panel’s rulings.

The outcome under the 2021 Code was:

No Breach of Clause 5.1    [Panel’s breach ruling overturned at appeal]

Requirement to maintain high standards at all times

No Breach of Clause 8.3

Requirement to certify non-promotional material

No Breach of Clause 26.1

Requirement not to advertise prescription only medicines to the public

No Breach of Clause 26.2

 

Requirement that information about prescription only medicines which is made available to the public must be factual, balanced, must not raise unfounded hopes of successful treatment or encourage the public to ask their health professional to prescribe a specific prescription only medicine.

This summary is not intended to be read in isolation.
For full details, please see the full case report below.